Convalescent Plasma in COVID-19

Overview

Journal HCA Healthc J Med

Specialty Health Services

Date 2023 Jul 10

PMID 37424714

Authors

Ranjit S Banwait

Joshua K Salabei

Troy J Fishman

Uma G Iyer

Affiliations

Soon will be listed here.

Abstract

Description The recent pandemic of SARS-CoV-2, which causes novel coronavirus disease 2019 (Covid-19), has had devastating impact on a global and national scale. In order to overcome this outbreak it is imperative we find treatments that are safe and effective. To date, no definitive treatment is available that can curtail the spread of this viral syndrome. Convalescent plasma (CP) is one such option that has repeatedly served as an important tool in treatment of various bacterial and viral infections, especially in the setting of no specific antimicrobial or vaccination against an infectious disease. Herein, we review the history of CP, prior usage of CP in various infections and pandemics to date, mechanism of action of the same and conclude with a brief overview of the experience gained so far with use of CP in COVID-19.

Citing Articles

Physicians at the crossroad of prognosis and faith: practical help communicating with patients and families during the COVID-19 pandemic.

Salabei J, Fishman T, Schwartz S, Okonoboh P, Iyer U J Community Hosp Intern Med Perspect. 2021; 11(3):293-295.

PMID: 34234895 PMC: 8118447. DOI: 10.1080/20009666.2021.1890340.

Non-pharmaceutical intervention to reduce COVID-19 impact in Argentina.

Garcia-Violini D, Sanchez-Pena R, Moscoso-Vasquez M, Garelli F ISA Trans. 2021; 124:225-235.

PMID: 34175123 PMC: 8214935. DOI: 10.1016/j.isatra.2021.06.024.

Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense.

Abdalla A, Xie J, Junaid K, Younas S, Elsaman T, Abosalif K Bosn J Basic Med Sci. 2021; 21(5):515-527.

PMID: 33714258 PMC: 8381213. DOI: 10.17305/bjbms.2020.5543.

COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation.

Salabei J, Fishman T, Asnake Z, Ali A, Iyer U Heart Lung. 2021; 50(2):357-360.

PMID: 33524866 PMC: 7816593. DOI: 10.1016/j.hrtlng.2021.01.011.

References

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

Casadevall A, Dadachova E, Pirofski L . Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004; 2(9):695-703. DOI: 10.1038/nrmicro974. View

Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H . Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019; 4(4). PMC: 6478436. DOI: 10.1172/jci.insight.123158. View

Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T . Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016; 17(9):1102-8. PMC: 4994874. DOI: 10.1038/ni.3515. View

Sahr F, Ansumana R, Massaquoi T, Idriss B, Sesay F, Lamin J . Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect. 2016; 74(3):302-309. PMC: 7112610. DOI: 10.1016/j.jinf.2016.11.009. View

Zeng Q, Yu Z, Gou J, Li G, Ma S, Zhang G . Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020; 222(1):38-43. PMC: 7197534. DOI: 10.1093/infdis/jiaa228. View

Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View

10.

Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M . Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999; 179 Suppl 1:S18-23. DOI: 10.1086/514298. View

11.

Casadevall A, Scharff M . Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995; 21(1):150-61. PMC: 7197598. DOI: 10.1093/clinids/21.1.150. View

12.

Goncalvez A, Engle R, St Claire M, Purcell R, Lai C . Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007; 104(22):9422-7. PMC: 1868655. DOI: 10.1073/pnas.0703498104. View

13.

Zhou B, Zhong N, Guan Y . Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007; 357(14):1450-1. DOI: 10.1056/NEJMc070359. View

14.

Lu L, Suscovich T, Fortune S, Alter G . Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2017; 18(1):46-61. PMC: 6369690. DOI: 10.1038/nri.2017.106. View

15.

Hawkes R . ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS. Aust J Exp Biol Med Sci. 1964; 42:465-82. DOI: 10.1038/icb.1964.44. View

16.

Winkler A, Koepsell S . The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol. 2015; 22(6):521-6. DOI: 10.1097/MOH.0000000000000191. View

17.

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A . Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020; 92(9):1475-1483. PMC: 7267113. DOI: 10.1002/jmv.25961. View

18.

Casadevall A, Scharff M . Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994; 38(8):1695-702. PMC: 284624. DOI: 10.1128/AAC.38.8.1695. View

19.

GOOD R, Lorenz E . Historic aspects of intravenous immunoglobulin therapy. Cancer. 1991; 68(6 Suppl):1415-21. DOI: 10.1002/1097-0142(19910915)68:6+<1415::aid-cncr2820681402>3.0.co;2-0. View

20.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View